SG11201909334TA - Proteins for the treatment of epithelial barrier function disorders - Google Patents
Proteins for the treatment of epithelial barrier function disordersInfo
- Publication number
- SG11201909334TA SG11201909334TA SG11201909334TA SG11201909334TA SG 11201909334T A SG11201909334T A SG 11201909334TA SG 11201909334T A SG11201909334T A SG 11201909334TA SG 11201909334T A SG11201909334T A SG 11201909334TA
- Authority
- SG
- Singapore
- Prior art keywords
- avenue
- allerton
- genome
- san francisco
- california
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 6
- 108090000623 proteins and genes Proteins 0.000 title abstract 6
- 230000004890 epithelial barrier function Effects 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 241000234282 Allium Species 0.000 abstract 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 abstract 1
- 206010009900 Colitis ulcerative Diseases 0.000 abstract 1
- 208000011231 Crohn disease Diseases 0.000 abstract 1
- 206010017943 Gastrointestinal conditions Diseases 0.000 abstract 1
- 208000017189 Gastrointestinal inflammatory disease Diseases 0.000 abstract 1
- 235000003332 Ilex aquifolium Nutrition 0.000 abstract 1
- 235000002296 Ilex sandwicensis Nutrition 0.000 abstract 1
- 235000002294 Ilex volkensiana Nutrition 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract 1
- 230000004888 barrier function Effects 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 210000002919 epithelial cell Anatomy 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Prostheses (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762482963P | 2017-04-07 | 2017-04-07 | |
| US201762607706P | 2017-12-19 | 2017-12-19 | |
| US201762611334P | 2017-12-28 | 2017-12-28 | |
| PCT/US2018/026447 WO2018187682A1 (en) | 2017-04-07 | 2018-04-06 | Proteins for the treatment of epithelial barrier function disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201909334TA true SG11201909334TA (en) | 2019-11-28 |
Family
ID=63710147
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201909334T SG11201909334TA (en) | 2017-04-07 | 2018-04-06 | Proteins for the treatment of epithelial barrier function disorders |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11207376B2 (enExample) |
| EP (1) | EP3606542B1 (enExample) |
| JP (2) | JP7789303B2 (enExample) |
| KR (2) | KR20200003821A (enExample) |
| CN (1) | CN110769844B (enExample) |
| AU (2) | AU2018248324B2 (enExample) |
| CA (1) | CA3059354A1 (enExample) |
| IL (1) | IL269853A (enExample) |
| MX (2) | MX393998B (enExample) |
| SG (1) | SG11201909334TA (enExample) |
| TW (1) | TWI797116B (enExample) |
| WO (1) | WO2018187682A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11207376B2 (en) | 2017-04-07 | 2021-12-28 | Second Genome, Inc. | Proteins for the treatment of epithelial barrier function disorders |
| US11666627B2 (en) | 2017-04-07 | 2023-06-06 | Second Genome, Inc. | Proteins for the treatment of epithelial barrier function disorders |
| WO2019195859A1 (en) * | 2018-04-06 | 2019-10-10 | Second Genome, Inc. | Proteins for the treatment of epithelial barrier function disorders |
| WO2020077010A1 (en) * | 2018-10-09 | 2020-04-16 | Second Genome, Inc. | Lactococcus lactis expression system for delivering proteins efficacious for the treatment of epithelial barrier function disorders |
| JP2022544992A (ja) * | 2019-08-21 | 2022-10-24 | アストラゼネカ・コラボレイション・ベンチャーズ・リミテッド・ライアビリティ・カンパニー | クローン病を治療するためのブラジクマブの使用 |
| WO2021139766A1 (en) * | 2020-01-10 | 2021-07-15 | Huang Chih Hung | Peptide interacting with toll-like receptor 2 and the composition comprising the same |
| CN113773364B (zh) * | 2021-08-25 | 2023-04-28 | 无锡市儿童医院 | 小分子肽及其制备方法和应用 |
| EP4611774A2 (en) * | 2022-11-04 | 2025-09-10 | MiNK Therapeutics, Inc. | B-cell maturation antigen (bcma) chimeric antigen receptor invariant natural killer t cells and uses thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5856457A (en) | 1991-03-29 | 1999-01-05 | Genentech, Inc. | Nucleic acids encoding a human IL-8 receptor |
| US6734289B2 (en) | 2001-03-29 | 2004-05-11 | The University Of Chicago | Gastrokines and derived peptides including inhibitors |
| US20060189526A1 (en) | 2002-04-24 | 2006-08-24 | Podolsky Daniel K | Compositions containing an intestinal trefoil peptide and a mucoadhesive |
| AR053579A1 (es) * | 2005-04-15 | 2007-05-09 | Genentech Inc | Tratamiento de la enfermedad inflamatoria intestinal (eii) |
| ES2568938T3 (es) | 2009-04-28 | 2016-05-05 | Vanderbilt University | Composiciones y procedimientos de tratamiento de trastornos que implican apoptosis de células epiteliales |
| GB201117313D0 (en) * | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
| JP2014093482A (ja) | 2012-11-06 | 2014-05-19 | Toshiba Corp | 固体撮像装置の製造方法および固体撮像装置 |
| GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
| WO2015014973A2 (en) * | 2013-07-31 | 2015-02-05 | Institut National De La Recherche Agronomique | Use of specific glycoside phosphorylases for the implementation of phosphorolysis or reverse phosphorolysis reactions |
| EP3662917A1 (en) | 2015-06-15 | 2020-06-10 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US11666627B2 (en) * | 2017-04-07 | 2023-06-06 | Second Genome, Inc. | Proteins for the treatment of epithelial barrier function disorders |
| US11207376B2 (en) | 2017-04-07 | 2021-12-28 | Second Genome, Inc. | Proteins for the treatment of epithelial barrier function disorders |
| US11174293B2 (en) | 2017-06-02 | 2021-11-16 | Second Genome, Inc. | Proteins for the treatment of epithelial barrier function disorders |
| WO2019195859A1 (en) | 2018-04-06 | 2019-10-10 | Second Genome, Inc. | Proteins for the treatment of epithelial barrier function disorders |
-
2018
- 2018-04-06 US US16/603,507 patent/US11207376B2/en active Active
- 2018-04-06 KR KR1020197032830A patent/KR20200003821A/ko not_active Ceased
- 2018-04-06 CN CN201880037987.0A patent/CN110769844B/zh not_active Expired - Fee Related
- 2018-04-06 SG SG11201909334T patent/SG11201909334TA/en unknown
- 2018-04-06 US US15/947,263 patent/US10251933B2/en active Active
- 2018-04-06 JP JP2019554976A patent/JP7789303B2/ja active Active
- 2018-04-06 CA CA3059354A patent/CA3059354A1/en active Pending
- 2018-04-06 WO PCT/US2018/026447 patent/WO2018187682A1/en not_active Ceased
- 2018-04-06 AU AU2018248324A patent/AU2018248324B2/en active Active
- 2018-04-06 EP EP18781398.5A patent/EP3606542B1/en active Active
- 2018-04-06 MX MX2019012051A patent/MX393998B/es unknown
- 2018-04-06 KR KR1020237032575A patent/KR102903277B1/ko active Active
- 2018-04-09 TW TW107112165A patent/TWI797116B/zh active
-
2019
- 2019-10-06 IL IL26985319A patent/IL269853A/en unknown
- 2019-10-07 MX MX2022008842A patent/MX2022008842A/es unknown
-
2023
- 2023-04-24 US US18/305,899 patent/US12661383B2/en active Active
- 2023-05-08 AU AU2023202844A patent/AU2023202844A1/en not_active Abandoned
- 2023-12-11 JP JP2023208379A patent/JP2024037834A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL269853A (en) | 2019-11-28 |
| MX393998B (es) | 2025-03-24 |
| KR20230144097A (ko) | 2023-10-13 |
| US20240066095A1 (en) | 2024-02-29 |
| KR20200003821A (ko) | 2020-01-10 |
| US20180289770A1 (en) | 2018-10-11 |
| EP3606542B1 (en) | 2026-06-10 |
| US10251933B2 (en) | 2019-04-09 |
| US12661383B2 (en) | 2026-06-23 |
| JP2024037834A (ja) | 2024-03-19 |
| CN110769844A (zh) | 2020-02-07 |
| CN110769844B (zh) | 2025-01-21 |
| WO2018187682A1 (en) | 2018-10-11 |
| TWI797116B (zh) | 2023-04-01 |
| AU2023202844A1 (en) | 2023-07-06 |
| TW201841649A (zh) | 2018-12-01 |
| US11207376B2 (en) | 2021-12-28 |
| MX2019012051A (es) | 2020-02-12 |
| MX2022008842A (es) | 2022-08-02 |
| JP7789303B2 (ja) | 2025-12-22 |
| EP3606542A4 (en) | 2021-01-20 |
| US20200148728A1 (en) | 2020-05-14 |
| CA3059354A1 (en) | 2018-10-11 |
| AU2018248324B2 (en) | 2023-02-09 |
| EP3606542A1 (en) | 2020-02-12 |
| AU2018248324A1 (en) | 2019-10-31 |
| JP2020516615A (ja) | 2020-06-11 |
| KR102903277B1 (ko) | 2025-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201901020RA (en) | Anti-siglec-7 antibodies for the treatment of cancer | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201909572QA (en) | Methods for the treatment of subjects having a hepatitis b virus (hbv) infection | |
| SG11201811151PA (en) | Extracellular vesicle comprising a fusion protein having fc binding capacity | |
| SG11201908650PA (en) | Optimized antibody compositions for treatment of ocular disorders | |
| SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
| SG11201806845VA (en) | Moisturizing compositions and uses thereof | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201807912SA (en) | Vaccine against rsv | |
| SG11201811549UA (en) | Boronic acid derivatives and therapeutic uses thereof | |
| SG11201907420VA (en) | Inhibition of smarca2 for treatment of cancer | |
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
| SG11201810927QA (en) | Pd-l1-specific antibodies and methods of using the same | |
| SG11201907023UA (en) | Method of reducing neutropenia | |
| SG11201811442UA (en) | Formulation of a peptide vaccine | |
| SG11201906301UA (en) | Methods of manufacture of nut flours and formulations for oral immunotherapy | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201811559WA (en) | Cancer treatment combinations | |
| SG11201806342SA (en) | Glucagon and glp-1 co-agonists for the treatment of obesity | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201809100QA (en) | Use of gram negative species to treat atopic dermatitis |